Abstract
Until recently, skeletal myoblasts (SkMBs) have been the most widely used cells in basic research and clinical trials of cellbased therapy for cardiac repair and regeneration. Although SkMB engraftment into the postinfarcted heart has been consistently found to improve cardiac contractile function, the underlying therapeutic mechanisms remain still a matter of controversy and debate. This is basically because SkMBs do not attain a cardiac-like phenotype once homed into the diseased heart nor they form a contractile tissue functionally coupled with the surrounding viable myocardium. This issue of concern has generated the idea that the cardiotropic action of SkMBs may depend on the release of paracrine factors. However, the paracrine hypothesis still remains ill-defined, particularly concerning the identification of the whole spectrum of cell-derived soluble factors and details on their cardiac effects. In this context, the possibility to genetically engineering SkMBs to potentate their paracrine attitudes appears particularly attractive and is actually raising great expectation. Aim of the present review is not to cover all the aspects of cell-based therapy with SkMBs, as this has been the object of previous exhaustive reviews in this field. Rather, we focused on novel aspects underlying the interactions between SkMBs and the host cardiac tissues which may be relevant for directing the future basic and applied research on SkMB transplantation for postischemic cardiac dysfunction.
Keywords: Skeletal myoblast, cardiac regeneration, paracrine factors, sphingosine-1-phosphate, relaxin
Current Pharmaceutical Design
Title: Skeletal Myoblasts for Heart Regeneration and Repair: State of the Art and Perspectives on the Mechanisms for Functional Cardiac Benefits
Volume: 16 Issue: 8
Author(s): L. Formigli, S. Zecchi-Orlandini, E. Meacci and D. Bani
Affiliation:
Keywords: Skeletal myoblast, cardiac regeneration, paracrine factors, sphingosine-1-phosphate, relaxin
Abstract: Until recently, skeletal myoblasts (SkMBs) have been the most widely used cells in basic research and clinical trials of cellbased therapy for cardiac repair and regeneration. Although SkMB engraftment into the postinfarcted heart has been consistently found to improve cardiac contractile function, the underlying therapeutic mechanisms remain still a matter of controversy and debate. This is basically because SkMBs do not attain a cardiac-like phenotype once homed into the diseased heart nor they form a contractile tissue functionally coupled with the surrounding viable myocardium. This issue of concern has generated the idea that the cardiotropic action of SkMBs may depend on the release of paracrine factors. However, the paracrine hypothesis still remains ill-defined, particularly concerning the identification of the whole spectrum of cell-derived soluble factors and details on their cardiac effects. In this context, the possibility to genetically engineering SkMBs to potentate their paracrine attitudes appears particularly attractive and is actually raising great expectation. Aim of the present review is not to cover all the aspects of cell-based therapy with SkMBs, as this has been the object of previous exhaustive reviews in this field. Rather, we focused on novel aspects underlying the interactions between SkMBs and the host cardiac tissues which may be relevant for directing the future basic and applied research on SkMB transplantation for postischemic cardiac dysfunction.
Export Options
About this article
Cite this article as:
Formigli L., Zecchi-Orlandini S., Meacci E. and Bani D., Skeletal Myoblasts for Heart Regeneration and Repair: State of the Art and Perspectives on the Mechanisms for Functional Cardiac Benefits, Current Pharmaceutical Design 2010; 16 (8) . https://dx.doi.org/10.2174/138161210790883390
DOI https://dx.doi.org/10.2174/138161210790883390 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Mitochondria Damage in the Pathogenesis of Diabetic Retinopathy and in the Metabolic Memory Associated with its Continued Progression
Current Medicinal Chemistry Cardiac Calmodulin Kinase: A Potential Target for Drug Design
Current Medicinal Chemistry Inverse Regulation of MMP-9 and MMP-2 in Long-Term Follow-up After Acute Coronary Syndrome: Lack of Correlation with Platelet and Endothelial Cell Activation Markers
Vascular Disease Prevention (Discontinued) Patent Selections
Recent Patents on Cardiovascular Drug Discovery Regulative Roles of Ghrelin in Ingestive Behavior, Upper Gastrointestinal Motility, and Secretion
Current Nutrition & Food Science Editorial (Thematic Issue: Protection, Repair and Regeneration of Achybreaky Heart)
Current Drug Targets Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design Meet Our Regional Editor
Current Vascular Pharmacology Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology Metallothioneins and Cancer
Current Protein & Peptide Science Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Current Pharmaceutical Design Inhibitory Effect of PD-1/PD-L1 and Blockade Immunotherapy in Leukemia
Combinatorial Chemistry & High Throughput Screening New Cell Therapy Using Bone Marrow-Derived Stem Cells/Endothelial Progenitor Cells to Accelerate Neovascularization in Healing of Experimental Ulcerative Colitis
Current Pharmaceutical Design Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Na/K-ATPase Signaling: A New Approach to Control Oxidative Stress
Current Pharmaceutical Design